---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-119439"
form_type: "8-K"
ticker: "ABPO"
cik: "0001893219"
company_name: "Abpro Holdings, Inc."
filed_at: "2025-12-09T23:59:59+00:00"
generated_at: "2026-05-16T13:50:27.063806+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Abpro Holdings granted Nasdaq extension to regain listing compliance

## Summary
- Received extension from Nasdaq Hearings Panel to achieve full compliance; deadline not specified.
- Completed reverse stock split on Nov 3; plans to increase stockholders' equity and may transfer markets.
- Has access to up to $44M in equity financing to fund operations and milestones through 2026.
- Achieved ~60% reduction in operating expenses vs prior year; lead candidate ABP-102 on track for 2026 first-in-human trials.
- Lead candidate ABP-102 developed with Celltrion; DiversImmune and MultiMab platforms advancing.

## SEC filing metadata
- accession: 0001213900-25-119439
- form_type: 8-K
- ticker: ABPO
- cik: 0001893219
- company_name: Abpro Holdings, Inc.
- filed_at: 2025-12-09T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1893219/000121390025119439/0001213900-25-119439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1893219/000121390025119439/ea0268922-8k_abpro.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-119439
- JSON: https://secwatch.observer/filing/0001213900-25-119439.json
- Plain text: https://secwatch.observer/filing/0001213900-25-119439.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.